Viatris (VTRS) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: acute, Alaska, bear, birth, bridge, build, carbon, cenerimod, channel, chronic, conform, content, costly, country, CRL, diverse, durable, enduring, engine, EPS, exceptionally, externally, greenhouse, Gx, holistically, Idorsia, imminent, imminently, impose, innovation, innovative, joint, JPO, Judicial, Korea, letter, line, Lupin, Luxembourg, Matrix, motivate, move, Multidistrict, NDA, OECD, Orbicular, overseeing, overturned, Pillar, postponing, proven, refusal, rehearing, rejected, renewable, Sawai, scale, scientific, selatogrel, STA, Stockholm, Swedish, tiered, touching, Towa, traditional, underpayment, unpredictable, upholding, weather, world

Removed: accelerating, account, achievable, achieved, achieving, acquiring, advance, amendment, arbitration, ASU, benchmark, Biogen, brand, built, California, cancelled, care, causation, circumstance, committed, compensate, complementary, contemplated, contract, convert, converted, cyclosporine, dealing, deducted, dental, directed, directing, discovery, disease, dispensing, dispute, divesting, downsizing, Dr, emulsion, enabling, English, expensed, expired, eye, FASB, fifty, formed, formula, foundation, fourteen, GmbH, high, hygiene, improve, Improving, Inhub, injunction, intermediary, invoice, Ireland, issue, knowledge, label, lenalidomide, lesser, LIBOR, London, MA, markup, merger, metric, monthly, neuropathic, NHS, noncurrent, Ocular, ophthalmic, ophthalmology, optimizing, organization, pain, pandemic, participating, past, percent, posed, pregabalin, preventing, pursuit, Ranbaxy, recognition, Reddy, reimbursed, remained, remove, repaid, responsibility, retaining, Sandoz, Scotland, Scottish, seasoned, Secretary, selling, settle, shift, Social, SOFR, sought, space, spectrum, stated, strategically, Subtopic, Sweden, timeframe, transitioning, treat, treatment, undertook, unmet, viable, visionary, voluntary, Wixela

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VTRS transcripts

VTRS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Viatris Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


			/s/ SCOTT A. SMITH
			Scott A. Smith
			Chief Executive Officer
			(Principal Executive Officer)

			/s/ THEODORA MISTRAS
			Theodora Mistras
			Chief Financial Officer
			(Principal Financial Officer)

Date: May 9, 2024

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.